<DOC>
	<DOCNO>NCT00755118</DOCNO>
	<brief_summary>The aim study evaluate efficacy effective drug alternate chemotherapy schedule pretreated patient mCRC , receive effective drug .</brief_summary>
	<brief_title>Lohp , 5-Fu/Lv Bevacizumab , Alternative With Cpt-11 , 5-Fu/Lv Cetuximab In Metastatic Crc</brief_title>
	<detailed_description>Colorectal cancer major cause death worldwide rank third incidence death cancer USA men woman . Incidence mortality decrease steadily past decade , 5-year survival patient diagnose 1996-2002 , 65 % . Although curative surgical resection possible 70-80 % patient diagnosis , almost half develop local or/and metastatic recurrence die disease . There currently three active cytotoxic agent show effective treatment advance colorectal cancer : 5-Fluorouracil combined Leucovorin ( 5-FU/LV ) , Irinotecan Oxaliplatin . During last year , median overall survival patient advance CRC substantially increase 12 month 21-22 month , combination chemotherapeutic agent administer . Combinations 5-Fluorouracil/Leucovorin ( 5-FU/LV ) either bolus ( Roswell Park ) infusional administration ( De Gramont schedule ) r weekly infusional ( AIO regimen ) , combine Irinotecan Oxaliplatin accept mainstay first line treatment . The advent target therapy expand treatment option patient mCRC.In particular , inhibition Epidermal Growth Factor Receptor ( EGFR ) angiogenesis block Vascular Endothelial Growth Factor ( VEGF ) use monoclonal antibody , lead improvement outcome patient mCRC . EGFR express CRCs . Cetuximab ( Erbitux ) chimeric monoclonal antibody specifically target EGFR . In combination Irinotecan , Cetuximab approve treatment EGFR-expressing mCRC , fail prior Irinotecan-based therapy , suggest Cetuximab may circumvent Irinotecan resistance . Bevacizumab ( Avastin ) monoclonal antibody Vascular Endothelial Growth Factor ( VEGF ) . In CRC , increase VEGF expression correlate invasiveness , vascular density , metastasis , recurrence prognosis . In phase 2 trial treatment CRC , addition bevacizumab FU/LV increase response rate , median time disease progression , median duration survival . Recently , show randomized phase 2 trial bevacizumab , combine irinotecan plus bolus FU/LV first line treatment metastatic CRC , oxaliplatin plus continuous FU/LV ( FOLFOX ) second-line treatment lead increased median survival , progression-free survival ( PFS ) , response rate compare cytotoxic chemotherapy alone .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically confirm locally advanced metastatic colorectal cancer Measurable evaluable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) ECOG performance status ≤ 2 Age 18 72 year Patients progress 1st line therapy FOLFOX/AVASTIN Adequate liver ( Bilirubin ≤ 1.5 upper normal limit , SGOT/SGPT ≤ 4 upper normal limit , ALP ≤ 2.5 upper normal limit ) , renal ( Creatinine ≤ 1.5 upper normal limit ) bone marrow ( ANC ≥ 1,500/mm3 , PLT ≥100,000/mm3 ) function Patients must able understand nature study Written inform consent Previous treatment effective drug metastatic colorectal cancer ( CPT11 , LOHP , 5FU/XELODA , Erbitux , Avastin ) History serious cardiac disease ( unstable angina , congestive heart failure , uncontrolled cardiac arrhythmia ) History myocardial infarction stroke within 6 month Clinically significant peripheral vascular disease History abdominal fistula , gastrointestinal perforation intraabdominal abscess within 28 day prior Day 0 Major surgical procedure , open biopsy , significant traumatic injury within 30 day prior Day 1 Presence central nervous system brain metastasis Evidence bleed diathesis coagulopathy Blood pressure &gt; 150/100 mmHg Pregnant lactate woman Life expectancy &lt; 3 month Previous radiotherapy within last 4 week &gt; 25 % bone marrow Metastatic infiltration liver &gt; 50 % Patients chronic diarrhea ( least 3 month ) partial bowel obstruction total colectomy Active infection require antibiotic Day 1 Second primary malignancy , except nonmelanoma skin cancer situ cervical cancer Psychiatric illness social situation would preclude study compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Metastatic colorectal cancer</keyword>
	<keyword>Second line</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>